Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSHA Taysha Gene Therapies, Inc.

Trading 06-11 14:10:47 EDT

5.62

+0.22

+4.07%

High5.70	Low5.30	Vol724.45K
Open5.41	D1 Closing5.40	Amplitude7.41%
Mkt Cap1.61B	Tradable Cap1.04B	Total Shares287.27M
T/O4.03M	T/O Rate0.39%	Tradable Shares185.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TSHA","market":"US","secType":"STK","nameCN":"Taysha Gene Therapies, Inc.","latestPrice":5.62,"timestamp":1781201437253,"preClose":5.4,"halted":0,"volume":724447,"delay":0,"changeRate":0.040740740740740695,"floatShares":185000000,"shares":287269885,"eps":-0.377498,"marketStatus":"Trading","change":0.22,"latestTime":"06-11 14:10:47 EDT","open":5.41,"high":5.7,"low":5.3,"amount":4025940.3352200002,"amplitude":0.074074,"askPrice":5.62,"askSize":100,"bidPrice":5.61,"bidSize":304,"shortable":3,"etf":0,"ttmEps":-0.377498,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781208000000},"marketStatusCode":2,"adr":0,"listingDate":1600920000000,"exchange":"NASDAQ","adjPreClose":5.4,"preHourTrading":{"tag":"盘前","latestPrice":5.44,"preClose":5.4,"latestTime":"08:49 EDT","volume":76,"amount":413.9100296,"timestamp":1781182156405,"change":0.04,"changeRate":0.007407,"amplitude":0.074074},"postHourTrading":{"tag":"盘后","latestPrice":5.44,"preClose":5.4,"latestTime":"19:35 EDT","volume":239696,"amount":1294394.63,"timestamp":1781134535336,"change":0.04,"changeRate":0.007407,"amplitude":0.007407},"volumeRatio":0.360248,"impliedVol":1.074,"impliedVolPercentile":0.6693},"requestUrl":"/m/hq/s/TSHA","defaultTab":"news","newsList":[{"id":"2641653110","title":"Taysha Gene Therapies grants new hires 714,700 RSUs, 468,600 options at $5.97 under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2641653110","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641653110?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:02","pubTimestamp":1780660957,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies granted four new employees 714,700 restricted stock units, representing common shares, under its 2023 Inducement Plan.It also issued stock options covering 468,600 common shares, priced at $5.97 per share, equal to the grant-date close.The options have a 10-year term, vest 25% after one year, then monthly over 36 months, subject to continued service.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL8n35ls:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4139","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4112","TSHA","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641110153","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641110153","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641110153?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:01","pubTimestamp":1780660860,"startTime":"0","endTime":"0","summary":"DALLAS, June  05, 2026  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307344/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","TSHA","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640692961","title":"Taysha Gene Therapies Shareholders Back Governance and Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2640692961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640692961?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:44","pubTimestamp":1780436642,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies ( ($TSHA) ) has provided an update. On June 1, 2026, Taysha Gene Therapies, Inc. held its 2026 annual meeting of stockholders...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-shareholders-back-governance-and-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-shareholders-back-governance-and-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640923787","title":"Taysha Gene Therapies shareholders elected two directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640923787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640923787?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:09","pubTimestamp":1780430969,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies held its annual shareholder meeting on June 1, 2026.Shareholders backed an annual cadence for future advisory votes on named executive officer pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL1J1ZBC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637450143","title":"ASPIRE Rett Syndrome Trial Puts Taysha’s TSHA-102 Gene Therapy in Focus for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2637450143","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637450143?lang=en_us&edition=fundamental","pubTime":"2026-05-23 00:35","pubTimestamp":1779467722,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. ($TSHA) announced an update on their ongoing clinical study. The ASPIRE study is a new trial sponsored by Taysha Gene T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aspire-rett-syndrome-trial-puts-tayshas-tsha-102-gene-therapy-in-focus-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aspire-rett-syndrome-trial-puts-tayshas-tsha-102-gene-therapy-in-focus-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ISBC","TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634040371","title":"A Look At Taysha Gene Therapies (TSHA) Valuation After FDA Alignment On TSHA-102 BLA Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2634040371","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634040371?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:24","pubTimestamp":1778480661,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (TSHA) has reaffirmed FDA alignment on the Biologics License Application pathway for TSHA-102, including pivotal trial design and the potential use of a six month interim analysis for approval.\nSee our latest analysis for Taysha Gene Therapies.\nThe reaffirmed FDA pathway comes after a run in the stock, with a 30 day share price return of 45.95% and a 1 year total shareholder return of 217.62%. This signals strong momentum despite recent earnings losses and ongoing cash...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/a-look-at-taysha-gene-therapies-tsha-valuation-after-fda-ali","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/a-look-at-taysha-gene-therapies-tsha-valuation-after-fda-ali","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4139","LABU","BK4588","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634427379","title":"Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2634427379","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634427379?lang=en_us&edition=fundamental","pubTime":"2026-05-11 08:11","pubTimestamp":1778458267,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (($TSHA)) has held its Q1 earnings call. Read on for the main highlights of the call. Taysha Gene Therapies’ latest ear...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-ramps-up-ahead-of-tsha-102-bla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-ramps-up-ahead-of-tsha-102-bla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633497123","title":"Whitney Ijem Reiterates Buy Rating and Maintains $17 Price Target on Clinical Momentum and Strong Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2633497123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633497123?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:58","pubTimestamp":1778162302,"startTime":"0","endTime":"0","summary":"Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies, retaining the price target of $17.00. Whitney Ijem has ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/whitney-ijem-reiterates-buy-rating-and-maintains-17-price-target-on-clinical-momentum-and-strong-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/whitney-ijem-reiterates-buy-rating-and-maintains-17-price-target-on-clinical-momentum-and-strong-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633340194","title":"Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633340194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633340194?lang=en_us&edition=fundamental","pubTime":"2026-05-07 13:59","pubTimestamp":1778133578,"startTime":"0","endTime":"0","summary":"“We continued to execute our clinical development strategy for TSHA-102 and recently reaffirmed alignment with the FDA on our pathway to a BLA fili...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-reports-q1-eps-12c-consensus-10c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-reports-q1-eps-12c-consensus-10c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633550811","title":"Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633550811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633550811?lang=en_us&edition=fundamental","pubTime":"2026-05-07 02:55","pubTimestamp":1778093733,"startTime":"0","endTime":"0","summary":"In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Taysha Gene Therapies, with a price target of $12.00. L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-remains-a-buy-on-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-remains-a-buy-on-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633132222","title":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633132222","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633132222?lang=en_us&edition=fundamental","pubTime":"2026-05-06 23:27","pubTimestamp":1778081232,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings SummaryTaysha Gene Therapies Inc TSHA.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL8N41J2P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138489","title":"Taysha Gene Therapies Q1 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138489","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138489?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:08","pubTimestamp":1778069326,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Q1 net loss widens on higher R&D costsOverviewU.S. gene therapy developer's net loss widened on higher R&D costsHigher expenses driven by BLA-enabling manufacturing and clinical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J0N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138193","title":"Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138193","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138193?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:06","pubTimestamp":1778069175,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 50 percent decrease over losses of $(0.08) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52317998/taysha-gene-therapies-q1-eps-0-12-misses-0-10-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138386","title":"BRIEF-Taysha Gene Therapies Q1 Net Income USD -42.41 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138386","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138386?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068847,"startTime":"0","endTime":"0","summary":"BRIEF-Taysha Gene Therapies Q1 Net Income USD -42.41 Million\n\n\nMay 06 (Reuters) - Taysha Gene Therapies Q1 operating expenses USD 43.486 million.\n\nQ1 operating income USD -43.486 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXD25841:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138866","title":"Taysha Gene Therapies Q1 Operating Income USD -43.486 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138866?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXD25841:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633653133","title":"Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633653133","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633653133?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068800,"startTime":"0","endTime":"0","summary":"Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recen","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288743/0/en/Taysha-Gene-Therapies-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2517655374.HKD","CNS","IT","BK4135","BK4585","LU0267386448.USD","LU2237443465.HKD","LU0170899867.USD","LU2746668461.USD","BK4139","LU2237443978.SGD","LU2362541513.USD","BK4006","LU0107464264.USD","LU1363072403.SGD","IE00BFXG1179.USD","BK4134","LU1814569148.SGD","LU0882574139.USD","LU2237443895.HKD","IE00B1BXHZ80.USD","LU0154245756.USD","LU2362540622.SGD","BK4588","TSHA","LU2746668974.SGD","IE00BZ1G4Q59.USD","LU2237443549.SGD","LU2237443382.USD","LU0149725797.USD","LU2517655028.SGD","IE00BKVL7J92.USD","LU2362541273.HKD","LU2517655291.USD","IE00BHPRN162.USD","LU0154245673.USD","LU0971096721.USD","CMC","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632427076","title":"Taysha Gene Therapies grants 188,000 RSUs to five new employees under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2632427076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632427076?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:06","pubTimestamp":1777666001,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies granted 188,000 restricted stock units to five newly hired employees on May 1, 2026.Awards were issued under Taysha 2023 Inducement Plan.RSUs vest in four equal annual installments starting on first anniversary of vesting commencement date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL3CmlTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","SG9999014039.USD","NDAQ","SG9999014013.SGD","IE00BN0W2W23.USD","LU0314104364.USD","BK4585","TSHA","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632006642","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632006642","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632006642?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:05","pubTimestamp":1777665900,"startTime":"0","endTime":"0","summary":"DALLAS, May  01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3286205/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","TSHA","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631519829","title":"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2631519829","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631519829?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:00","pubTimestamp":1777464000,"startTime":"0","endTime":"0","summary":"DALLAS, April  29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283681/0/en/Taysha-Gene-Therapies-to-Release-First-Quarter-2026-Financial-Results-and-Host-Conference-Call-and-Webcast-on-May-6.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4181","BK4588","CNS","BK4218","HST","BK4135","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630534841","title":"Taysha Gene Therapies to present new TSHA-102 preclinical data at ASGCT annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630534841","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630534841?lang=en_us&edition=fundamental","pubTime":"2026-04-28 05:21","pubTimestamp":1777324904,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies will present new preclinical in vitro data on TSHA-102 at ASGCT Annual Meeting in Boston on May 11-15, 2026.Poster presentation scheduled for May 14, 2026, 5:00-6:30 PM ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL2DRfSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","TSHA","BK4588","LU2210149790.SGD","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","IE00BKPKM429.USD","BK4112","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tayshagtx.com","stockEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.2082},{"period":"3month","weight":0.1714},{"period":"6month","weight":-0.0674},{"period":"1year","weight":1.069},{"period":"ytd","weight":-0.0182}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.177745},{"month":2,"riseRate":0.5,"avgChangeRate":0.091899},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104956},{"month":4,"riseRate":0.5,"avgChangeRate":0.079391},{"month":5,"riseRate":0.333333,"avgChangeRate":0.032889},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.037965},{"month":7,"riseRate":0.6,"avgChangeRate":0.019307},{"month":8,"riseRate":0.8,"avgChangeRate":0.75256},{"month":9,"riseRate":0.2,"avgChangeRate":-0.089587},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.04036},{"month":11,"riseRate":0.5,"avgChangeRate":0.137875},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.034429}],"exchange":"NASDAQ","name":"Taysha Gene Therapies, Inc.","nameEN":"Taysha Gene Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Taysha Gene Therapies, Inc.,TSHA,Taysha Gene Therapies, Inc.股票,Taysha Gene Therapies, Inc.股票老虎,Taysha Gene Therapies, Inc.股票老虎国际,Taysha Gene Therapies, Inc.行情,Taysha Gene Therapies, Inc.股票行情,Taysha Gene Therapies, Inc.股价,Taysha Gene Therapies, Inc.股市,Taysha Gene Therapies, Inc.股票价格,Taysha Gene Therapies, Inc.股票交易,Taysha Gene Therapies, Inc.股票购买,Taysha Gene Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction